(Stroke. 2002;33:1934.)
© 2002 American Heart Association, Inc.
ASA/AAN Scientific Statement |
From the Department of Neurology (B.M.C.), Arizona Health Science Center, Tucson, Ariz; Department of Neurology (L.S.W.), Indiana University School of Medicine, Research Scientist, Regenstrief Institute for Health Care, Indianapolis, Ind; Department of Neurology (L.B.G.), Duke Center for Cerebrovascular Disease, Duke Center for Clinical Health Policy Research, and Durham VA Medical Center, Durham, NC; Department of Neurology (J.F.M.), Mayo Clinic/Jacksonville, Fla; Texas Neurology, PC (D.H.), Dallas, Tex; Department of Neurology (S.C.), Wayne State University, Detroit, Mich; Departments of Neurology and Health (K.C.J.), Evaluation Sciences, University of Virginia, Charlottesville; Departments of Emergency Medicine and Neurology (S.S.), UCLA, and Department of Neurology (J.L.S.), UCLA School of Medicine, Los Angeles, Calif; Departments of Neurology & Epidemiology (L.B.M.), University of Texas, Houston; Department of Clinical Neurosciences (J.L.W.), Brown Medical School, Providence, RI; and Department of Neurology (S.R.L.), Mount Sinai School of Medicine, New York, NY.
Correspondence and reprint requests to American Academy of Neurology, 1080 Montreal Ave., St. Paul, MN 55116.
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
Stroke remains a common and costly problem worldwide, but substantial advances have been made in recent decades in understanding stroke mechanisms, risk factors, and therapies. Because thrombosis plays an important role in the pathogenesis of ischemic stroke, drugs that interfere with hemostasis and clot formation such as anticoagulants and platelet antiaggregants commonly are used in the management of cerebrovascular disease. Considerable evidence supports the use of certain antithrombotic drugs in stroke prevention. However, because of limited supportive data, the use of these agents in patients with acute ischemic stroke remains controversial.
In this report, we examine the published evidence relevant to the effects of anticoagulants and antiplatelet agents on acute ischemic stroke mortality, morbidity, and recurrence rates as well as associated ancillary benefits and risks of those treatments on the rates of deep vein thrombosis, pulmonary embolus, and cardiovascular complications. As part of these analyses, we also sought to determine whether there was evidence supporting differential efficacy of these drugs according to ischemic stroke subtypes.
Methods
To prepare this report, experienced neurologists with a special interest in stroke diagnosis and management were appointed by the Quality Standards Subcommittee (QSS) and the Therapeutics and Technology Assessment (TTA) Subcommittee of the American Academy of Neurology, and the Stroke Council and Science Advisory and Coordinating Committee (SACC) of the American Heart Association (AHA). The QSS, TTA, Stroke Council and SACC are each charged with the responsibility of preparing evidence-based reports pertaining to medical practice issues including stroke.
To facilitate the process of joint guideline
This article has been cited by other articles:
![]() |
K. M. Barrett and W. D. Freeman 71-Year-Old Woman With Loss of Right-Sided Vision and Cognitive Deficits Mayo Clin. Proc., June 1, 2008; 83(6): 708 - 711. [Full Text] [PDF] |
||||
![]() |
G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 630S - 669S. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T. Engelter, T. Brandt, S. Debette, V. Caso, C. Lichy, A. Pezzini, S. Abboud, A. Bersano, R. Dittrich, C. Grond-Ginsbach, et al. Antiplatelets Versus Anticoagulation in Cervical Artery Dissection Stroke, September 1, 2007; 38(9): 2605 - 2611. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, May 22, 2007; 115(20): e478 - e534. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke, May 1, 2007; 38(5): 1655 - 1711. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sandercock Immediate Anticoagulation for Acute Stroke in Atrial Fibrillation: No Stroke, December 1, 2006; 37(12): 3054 - 3055. [Full Text] [PDF] |
||||
![]() |
S. C. Smith Jr, J. Allen, S. N. Blair, R. O. Bonow, L. M. Brass, G. C. Fonarow, S. M. Grundy, L. Hiratzka, D. Jones, H. M. Krumholz, et al. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute J. Am. Coll. Cardiol., May 16, 2006; 47(10): 2130 - 2139. [Full Text] [PDF] |
||||
![]() |
S. C. Smith Jr, J. Allen, S. N. Blair, R. O. Bonow, L. M. Brass, G. C. Fonarow, S. M. Grundy, L. Hiratzka, D. Jones, H. M. Krumholz, et al. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute Circulation, May 16, 2006; 113(19): 2363 - 2372. [Full Text] [PDF] |
||||
![]() |
H. F. McGruder, J. B. Croft, and Z.-J. Zheng Characteristics of an "Ill-Defined" Diagnosis for Stroke: Opportunities for Improvement Stroke, March 1, 2006; 37(3): 781 - 789. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lam and C. M. Ruby Impact of an interdisciplinary team on drug therapy outcomes in a geriatric clinic Am. J. Health Syst. Pharm., March 15, 2005; 62(6): 626 - 629. [Full Text] [PDF] |
||||
![]() |
G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 483S - 512S. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. P. Adams Jr, R. J. Adams, T. Brott, G. J. del Zoppo, A. Furlan, L. B. Goldstein, R. L. Grubb, R. Higashida, C. Kidwell, T. G. Kwiatkowski, et al. Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association Stroke, April 1, 2003; 34(4): 1056 - 1083. [Full Text] [PDF] |
||||
![]() |
X. Wang, L. Xu, H. Wang, R. Grzanna, Y. Zhan, R. M. Knabb, J. M. Luettgen, T. A. Bozarth, R. A. Galemmo, P. C. Wong, et al. Inhibition of Factor Xa Reduces Ischemic Brain Damage After Thromboembolic Stroke in Rats Stroke, February 1, 2003; 34(2): 468 - 474. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sandercock Full Heparin Anticoagulation Should Not Be Used in Acute Ischemic Stroke Stroke, January 1, 2003; 34(1): 231 - 232. [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |